title: [Metastatic renal cell carcinoma: pretherapeutic approach before antiangiogenic treatment. A case report].
abstract: Antiangiogenic treatment initiation justifies a clinical and biological pretherapeutic assessment and a close follow-up of side effects according to each drug. Because of potential healing complications, a deadline of 4 weeks after surgery is recommended before starting antiangiogenic treatment. The optimal sequence and the potential role of neo-adjuvant therapies remain to define. In the absence of prospective data, nephrectomy is still recommended in renal cell carcinoma management.
authors.affiliation: Service d'Urologie, Hôpital Necker, rue de Sèvres, Paris cedex 15, France.
authors.forename: A
authors.initials: A
authors.lastname: Méjean
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: D
authors.initials: D
authors.lastname: Jacqmin
authors.forename: F
authors.initials: F
authors.lastname: Joly
authors.forename: S
authors.initials: S
authors.lastname: Négrier
authors.forename: G
authors.initials: G
authors.lastname: Pignot
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D007372:Interferons